Clinical Trials Browser

Phase 2/3 × INDUSTRY × Cisplatin × Clear all

NCT07063745 2026-03-17

MountainTAP-29

Phase 2/3 Recruiting

Lung Neoplasms

NCT07106762 2026-03-10

Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy

Phase 2/3 Recruiting

Urinary Bladder Neoplasms

NCT07129993 2026-03-05

Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma

Phase 2/3 Recruiting

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT07100080 2026-03-03

Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

Phase 2/3 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06236438 2026-02-23

LIVIGNO-4

Phase 2/3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT06225596 2026-02-17

Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)

Phase 2/3 Recruiting

Urinary Bladder Neoplasms

NCT04619797 2026-02-03

SKYSCRAPER-06

Phase 2/3 Completed

Carcinoma, Non-Small-Cell Lung

NCT07365319 2026-01-26

TeLuRide-008

Phase 2/3 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT05800015 2026-01-22

A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer

Phase 2/3 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07332533 2026-01-12

A Study of KN026-based Combination Therapy in HER2-positive Gastric Cancer

Phase 2/3 Not yet recruiting

Gastrointestinal

HER2-positive Gastric Cancer

NCT05893888 2025-06-15

Safety and Efficacy Study of PRV111 and PRV211 in Subjects With Oral Squamous Cell Carcinoma

Phase 2/3 Recruiting

Squamous Cell Carcinoma of Head and Neck

NCT06493552 2025-04-03

Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors

Phase 2/3 Recruiting

Carcinoma, Transitional Cell

NCT01249352 2025-03-31

NICE

Phase 2/3 Completed

Gastrointestinal

Adenocarcinoma, Esophageal Neoplasms

NCT06755515 2025-01-01

A Phase Ⅱ/Ⅲ Study of Rulonilimab Plus Chemotherapy± Bevacizumab for the First-Line Treatment of Persistent, Recurrent or Metastatic Cervical Cancer

Phase 2/3 Enrolling by invitation

Uterine Cervical Neoplasms

NCT05576272 2023-11-22

A Phase II/III Trial to Evaluate the Efficacy and Safety of QL1706 in Patients With Nasopharyngeal Carcinoma

Phase 2/3 Unknown

Nasopharyngeal Carcinoma

NCT04066491 2023-11-14

Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) in Participants With 1L BTC

Phase 2/3 Terminated

309 enrolled 17 charts

Gastrointestinal

Biliary Tract Neoplasms, Camurati-Engelmann Syndrome, Gallbladder Neoplasms, Cholangiocarcinoma

NCT03086993 2022-03-24

Percutaneous Hepatic Perfusion vs. Cisplatin/Gemcitabine in Patients With Intrahepatic Cholangiocarcinoma

Phase 2/3 Unknown

Gastrointestinal

Bile Duct Neoplasms, Cholangiocarcinoma

NCT04750083 2021-02-11

HX008 Plus Chemotherapy VS Pembrolizumab Plus Chemotherapy As the First-line Treatment in Participants With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer

Phase 2/3 Unknown

Nonsquamous Non-small Cell Lung Cancer

NCT01907100 2019-03-18

Nintedanib (BIBF 1120) in Mesothelioma

Phase 2/3 Terminated

545 enrolled 15 charts

Other solid neoplasmThoracic

Mesothelioma

NCT01383148 2017-01-05

TIME

Phase 2/3 Terminated

Carcinoma, Non-Small-Cell Lung

NCT00261703 2012-05-11

Docetaxel in Head and Neck Cancer

Phase 2/3 Completed

Head and Neck Neoplasms

NCT00401323 2011-01-20

Taxotere (Docetaxel) in 1st Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Phase 2/3 Completed

Head and Neck Neoplasms, Neoplasm Metastasis, Neoplasm Recurrence, Local

NCT00337532 2010-02-04

A Phase II Trial Neoadjuvant Paclitaxel and Cisplatin in Patients With Locally Advanced Head and Neck Cancer

Phase 2/3 Completed

Head and Neck Neoplasms